Zydus Lifesciences Limited has informed the Exchange about Rumour Verification - Regulation 30(11)

Litigation LossRegulatory & Legal View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.6%Reaction day

₹826.00

prior close

₹830.00

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)+1.6%-1.0% vs market

Pharmaceuticals peers, median of 147sector+0.4%+0.2% vs sector

On the reaction day the stock moved 1.0 pts less than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.3

10m

+0.3

15m

-0.4

30m

-0.9

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.6+1.6-1.0+0.4+0.2

Next day

+2.4+2.9-0.5+1.4+1.0

+3.1+3.1+0.0+1.7+1.4

+5.0+3.7+1.2+2.3+2.7

+6.5+3.4+3.1+3.5+3.1

+4.0+2.3+1.7+0.3+3.6

+7.5+3.5+4.0-0.1+7.6

15d

+7.2+5.6+1.6-0.1+7.3

+10.4+6.3+4.1+3.0+7.4

+15.5+5.9+9.6+3.3+12.2

+18.8+7.2+11.5+7.5+11.3

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 147Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences confirmed that the US District Court for the District of Delaware passed an order against the company on April 15, 2025, in a patent validity case filed by Astellas Pharma Inc. The litigation relates to a sustained-release formulation of mirabegron, marketed by Astellas under the brand Myrbetriq®. The company stated this court order is what caused the sharp movement in its share price on April 16. Zydus is currently evaluating the impact on its operations and the legal remedies available, including a likely appeal. It clarified that no settlement negotiations were in progress, as the matter is purely a patent dispute.

Likely market impact

Unfavourable US court order may delay or block Zydus's generic mirabegron launch in the US, weighing on near-term sentiment. However, the company still has legal remedies open, and the final financial impact remains under assessment.